MRNA
🟢 Moderna is trading 4.72% up today after Phase 3 trial met recurrence-free-survival endpoint
Moderna is trading 4.72% up at $190.70 after positive Phase 3 INTerpath-001 results for intismeran autogene with Merck’s Keytruda.
- The trial met its...
